16 September 2026 editorial review · Trial
Verapamil in newly diagnosed children: Egyptian randomized trial: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the trial evidence page →Primary-agent trial review — 16 September 2026
Assessment: Newly registered Egyptian recruiting Phase 2/3 trial, target 70, ages 10–18 within six weeks of diagnosis, six-month stimulated C-peptide; no results.
Registry: NCT07804849; RECRUITING; updated 2026-09-04; enrollment 70 (ESTIMATED); results not posted.
Endpoint comparison: Peak stimulated serum C-peptide concentration after mixed meal tolerance test (24 weeks).
Sources for this record: Oral Verapamil Among Newly Diagnosed Children and Adolescents With Type 1 Diabetes (NCT07804849) (registry).
Limits: Source access and review depth vary. Registry fields establish the registered study, not clinical benefit, product approval or current local access. Cited-source reachability alone was not treated as verification of its claims.